Complement Inhibitor Targeting C5a Signaling in Tumor Microenvironment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in effectively inhibiting tumor growth due to the immunosuppressive mechanisms employed by malignant tumors, particularly the role of the complement system in promoting tumor growth and immune evasion.
Innovation Solution
Administration of a complement inhibitor to reduce or prevent C5a receptor signaling in tumors, using agents such as C5a inhibitors, C3 inhibitors, or C4 inhibitors, which can be targeted to the tumor site or systemically administered, either alone or in combination with other anti-cancer treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement system is activated in tumor microenvironment, then inflammatory response and immune activation occur, but tumor growth is promoted and immune evasion is facilitated
Solution Approach 1:
The patent extracts and isolates the harmful C5a signaling pathway from the complement system. By specifically targeting and blocking C5a receptor signaling while leaving other complement functions intact, the invention removes the tumor-promoting aspect while preserving beneficial immune responses. This is achieved through selective administration of C5a inhibitors or C5a receptor blockers.
Solution Approach 2:
The patent introduces C5a inhibitors or C5a receptor blockers as intermediary substances that mediate between the complement system and tumor cells. These intermediaries selectively block the harmful C5a signaling pathway that promotes tumor growth and immune evasion, while allowing other complement-mediated anti-tumor mechanisms to remain functional.
2Adaptability or versatility
If myeloid-derived suppressor cells are recruited by tumors, then immune suppression occurs, but tumor progression is enhanced
Solution Approach 1:
The patent converts the harmful effect of C5a-mediated MDSC recruitment into a beneficial outcome by blocking this pathway. By administering C5a inhibitors, the treatment prevents MDSC accumulation and immune suppression, thereby converting the originally harmful C5a signaling into a therapeutic opportunity that enhances anti-tumor immunity.
3Productivity
If conventional anti-cancer therapies are administered, then tumor growth is inhibited, but side effects and immunosuppression occur
Solution Approach 1:
The patent changes the therapeutic parameter from non-specific cytotoxicity to specific pathway inhibition. By targeting C5a receptor signaling specifically rather than using broad-spectrum chemotherapeutics, the treatment achieves tumor growth inhibition through a different mechanism that spares healthy tissues from damage, thereby reducing side effects.
Data Source
AI summary
Methods for treating, preventing or delaying onset of tumor formation and other forms of cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumor microenvironment.